Investor Overview
Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is a research and development pharmaceutical company that develops enhanced, patented dermatology and healthcare products. Its primary motivation and focus is to license its patented Invisicare formulations to national and international dermatological, medical, cosmetic, skincare and consumer goods manufacturers and distributors. Skinvisible also produces a variety of skincare products for private label clients.
Shareholder's Information:
Authorized: 100,000,000 Common
Outstanding: 78,624,238
Public Float: 55%
Insider Ownership: 45%
Fiscal Year End: December 31
November 4, 2008
Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board
- A Strong International Strategy for Invisicare Is Put In Place
July 29, 2008
Skinvisible Offers 8 Hour Photostability for Parsol 1789
- UVA Sunscreen with Invisicare Available For International Licensing
June 11, 2008
Skinvisible Appoints New Vice President of Business Development & Marketing
- Strategic Plan for Invisicare Strengthens
CLICK HERE TO READ ALL NEWS RELEASES
|
Stock Information:
Go To Full SKVI Quote
OTC:SKVI at Google Finance
Press Releases
|
Skinvisible Web
PDF - 445k)